TP53 germline mutations in adult patients with adrenocortical carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages

  Herrmann, Leonie J M ^a   Heinze, Britta ^a   Fassnacht, Martin ^a   Willenberg, Holger S ^b   Quinkler, Marcus ^c   Reisch, Nicole ^d   Zink, Martina ^a   Allolio, Bruno ^a   Hahner, Stefanie ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CAUCASIAN; DISEASE COURSE; EXON; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; SPLICING DEFECT; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGE OF ONSET; AGED; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; REGISTRIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84858020426     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1982     Document Type: Article

References (54)

1. Li FP, Fraumeni Jr JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW 1988 A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362
2. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM 2001 Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20: 4621-4628 (Pubitemid 32762434)
3. Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D 2010 TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995-2001
4. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, Han JH, Lowstuter K, Longmate J, Sommer SS, Weitzel JN 2009 Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250-1256
5. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D 1994 High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst 86:1707-1710 (Pubitemid 24354633)
6. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DG, Harris M, Kelsey AM, Birch JM 1999 Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65:995-1006 (Pubitemid 30462956)
7. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M 2007 Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database (R15). Hum Mutat 28:622-629 (Pubitemid 46744292)
8. Libè R, Groussin L, Tissier F, Elie C, René-Corail F, Fratticci A, Jullian E, Beck-Peccoz P, Bertagna X, Gicquel C, Bertherat J 2007 Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin Cancer Res 13:844-850 (Pubitemid 46340358)
9. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, DeLacerda L, Rabin M, Cadwell C, Sampaio G, Cat I, Stratakis CA, Sandrini R 2001 An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci USA 98:9330-9335 (Pubitemid 32743916)
10. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW 2002 A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 9:12-16 (Pubitemid 34049172)
11. Figueiredo BC, Sandrini R, Zambetti GP, Pereira RM, Cheng C, Liu W, Lacerda L, Pianovski MA, Michalkiewicz E, Jenkins J, Rodriguez- Galindo C, Mastellaro MJ, Vianna S, Watanabe F, Sandrini F, Arram SB, Boffetta P, Ribeiro RC 2006 Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 43:91-96
12. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G, Le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, Landi S, Tavtigian SV, Hainaut P, Achatz MI 2010 Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of southern Brazil: evidence for a founder effect. Hum Mutat 31:143-150
13. Chompret A, Abel A, Stoppa-Lyonnet D, Brugiéres L, Pagés S, Feunteun J, Bonaïti-Pellié C 2001 Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet 38:43-47 (Pubitemid 32102322)
14. Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palù G, Boscaro M 2001 Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 145:207-212 (Pubitemid 32707608)
15. Pinto EM, Billerbeck AE, Fragoso MC, Mendonca BB, Latronico AC 2005 Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. J Clin Endocrinol Metab 90:2976-2981 (Pubitemid 40686352)
16. Ide H, Terado Y, Tokiwa S, Nishio K, Saito K, Isotani S, Kamiyama Y, Muto S, Imamura T, Horie S 2010 Novel germ line mutation p53-P177R in adult adrenocortical carcinoma producing neuron-specific enolase as a possible marker. Jpn J Clin Oncol 40:815-818
17. Varley JM, Chapman P, McGown G, Thorncroft M, White GR, Greaves MJ, Scott D, Spreadborough A, Tricker KJ, Birch JM, Evans DG, Reddel R, Camplejohn RS, Burn J, Boyle JM 1998 Genetic and functional studies of a germline TP53 splicing mutation in a Li-Fraumeni-like family. Oncogene 16:3291-3298 (Pubitemid 28330428)
18. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM, Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, Da Rocha JC, Vettore AL, Hainaut P 2007 The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245:96-102 (Pubitemid 44959345)
19. Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van't Veer LJ 2010 TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47:421-428
20. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, Lucon AM, Mendonca BB 2001 An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab 86:4970-4973 (Pubitemid 33020551)
21. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Führer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S, Allolio B, Group GAR 2010 Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 95:4925-4932
22. Brix D, Allolio B, Fenske W, Agha A, Dralle H, Jurowich C, Langer P, Mussack T, Nies C, Riedmiller H, Spahn M, Weismann D, Hahner S, Fassnacht M, Group GACR 2010 Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol 58:609-615
23. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B; German Adrenocortical Carcinoma Registry Group; European Network for the Study of Adrenal Tumors 2009 Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 115:243-250
24. Weiss LM 1984 Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169 (Pubitemid 14166767)
25. Turbett GR, Barnett TC, Dillon EK, Sellner LN 1996 Single-tube protocol for the extraction of DNA or RNA from paraffin-embedded tissues using a starch-based adhesive. Biotechniques 20:846-850, 852-853
26. Hahn M, Serth J, Fislage R, Wolfes H, Allhoff E, Jonas V, Pingoud A1993 Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron 1 of the human p53 gene. Clin Chem 39:549-550 (Pubitemid 23099034)
27. Jones MH, Nakamura Y 1992 Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chromosomes Cancer 5:89-90
28. Warneford SG, Witton LJ, Townsend ML, Rowe PB, Reddel RR, Dalla-Pozza L, Symonds G 1992 Germ-line splicing mutation of the p53 gene in a cancer-prone family. Cell Growth Differ 3:839-846
29. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, Doyle B, Jamieson NB, Oien KA, Lowy AM, Brunton VG, Frame MC, Evans TR, Sansom OJ 2010 Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA 107:246-251
30. Quek ML, Quinn DI, Daneshmand S, Stein JP 2003 Molecular prognostication in bladder cancer-a current perspective. Eur J Cancer 39:1501-1510 (Pubitemid 36833219)
31. Scartozzi M, Galizia E, Freddari F, Berardi R, Cellerino R, Cascinu S 2004 Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev 30: 451-459 (Pubitemid 38968125)
32. Marutani M, Tonoki H, Tada M, Takahashi M, Kashiwazaki H, Hida Y, Hamada J, Asaka M, Moriuchi T 1999 Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res 59:4765-4769 (Pubitemid 29472872)
33. Resnick MA, Inga A 2003 Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci USA 100:9934-9939 (Pubitemid 37087046)
34. Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G 2003 Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay. Oncogene 22:5252-5260 (Pubitemid 37056087)
35. Shiraishi K, Kato S, Han SY, Liu W, Otsuka K, Sakayori M, Ishida T, Takeda M, Kanamaru R, Ohuchi N, Ishioka C 2004 Isolation of temperature- sensitive p53 mutations from a comprehensive missense mutation library. J Biol Chem 279:348-355 (Pubitemid 38044833)
36. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G 1995 High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10:1217-1227
37. Pontén F, Berg C, Ahmadian A, Ren ZP, Nistér M, Lundeberg J, Uhlén M, Pontén J 1997 Molecular pathology in basal cell cancer with p53 as a genetic marker. Oncogene 15:1059-1067 (Pubitemid 27401960)
38. Heide I, Thiede C, Sonntag T, de Kant E, Neubauer A, Jonas S, Peter FJ, Neuhaus P, Herrmann R, Huhn D, Rochlitz CF 1997 The status of p53 in the metastatic progression of colorectal cancer. Eur J Cancer 33:1314-1322 (Pubitemid 27362779)
39. Chompret A, Brugières L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A, Hua D, Ligot L, Dondon MG, Bressac-de Paillerets B, Frébourg T, Lemerle J, Bonaïti-Pellié C, Feunteun J 2000 P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 82:1932-1937 (Pubitemid 30326453)
40. Pinto EM, Billerbeck AE, Villares MC, Domenice S, Mendonça BB, Latronico AC 2004 Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq Bras Endocrinol Metabol 48:647-650
41. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC 2010 Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res 70:4795-4800
42. Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugières L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, Bonaïti-Pellié C, Frébourg T 2008 Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45:535-538
43. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B 2006 Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab 91:4501-4504 (Pubitemid 44833430)
44. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, Kenn W, Hahner S, Allolio B, Flentje M 2009 Radiotherapy in adrenocortical carcinoma. Cancer 115:2816-2823
45. Sidhu S, Martin E, Gicquel C, Melki J, Clark SJ, Campbell P, Magarey CJ, Schulte KM, Röher HD, Delbridge L, Robinson BG 2005 Mutation and methylation analysis of TP53 in adrenal carcinogenesis. Eur J Surg Oncol 31:549-554 (Pubitemid 40724098)
46. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, Chrousos GP 1994 p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab 78:790-794
47. Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P, Magarey CJ, Russell CF, Schulte KM, Röher HD, Delbridge L, Robinson BG 2002 Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab 87: 3467-3474 (Pubitemid 34816405)
48. Zambetti GP 2007 The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol 213:370-373 (Pubitemid 47509715)
49. Ribeiro RC, Pinto EM, Zambetti GP 2010 Familial predisposition to adrenocortical tumors: clinical and biological features and management strategies. Best Pract Res Clin Endocrinol Metab 24:477-490
50. Lammens CR, Bleiker EM, Aaronson NK, Wagner A, Sijmons RH, Ausems MG, Vriends AH, Ruijs MW, van Os TA, Spruijt L, Gómez García EB, Cats A, Nagtegaal T, Verhoef S 2010 Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Fam Cancer 9:647-654
51. Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG 2000 Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer 88:1091-1098 (Pubitemid 30127671)
52. Momota H, Narita Y, Nariata Y, Miyakita Y, Hosono A, Makimoto A, Shibui S 2010 Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation. Pediatr Blood Cancer 55:577-579
53. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME 2006 Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet 43:289-294
54. Varley JM, McGown G, Thorncroft M, Santibanez-Koref MF, Kelsey AM, Tricker KJ, Evans DG, Birch JM 1997 Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57:3245-3252 (Pubitemid 27351742)